凹凸棒石粉对胆汁的吸附作用

目的 :探索降低反流胆汁中胆酸浓度的有效国产药物。方法 :以凹凸棒石粉或双八面体蒙脱石 (思密达 )吸附胆汁反流症患者胃液 ,检测并比较吸附前后胃液总胆酸和三羟胆酸含量 ,同时比较凹凸棒石粉剂和双八面体蒙脱石对胆酸的吸附能力。结果 :吸附前三羟胆酸和总胆酸含量分别为 (10 5 .71± 43.35 )μg/ ml和 (2 71.5 0± 77.5 0 )μmol/ L ,经凹凸棒石粉或双八面体蒙脱石吸附后三羟胆酸含量分别为 (32 .32± 18.36 )μg/ m l和 (2 9.13± 17.0 2 )μg/ ml,总胆酸含量分别为 (130 .0 1± 30 .94)μm ol / L与 (76 .90± 41.80 )μm ol/ L ,吸附前后三羟胆酸和总胆酸含量有显著差异 (P<0 .0 1) ,而经凹凸棒石粉或双八面体蒙脱石吸附后三羟胆酸和总胆酸含量无显著差异 (P>0 .0 5 )。 结论 :凹凸棒石粉对胆酸有较强的吸附作用 ,与双八面体蒙脱石无显著差异 ,有良好的临床应用前景。     

红参对家兔高血压性视网膜动脉硬化预防作用的光镜观察

目的:观察红参对视网膜、肾、脾动脉硬化的预防作用。方法:分3组观察家兔眼底血管病变反映全身小动脉硬化的程度。A 组为正常对照组,B 组为高血压模型组,均喂普通饲料,C 组为高血压模型组喂红参2g/d。(1)制作高血压动物模型;(2)观察视网膜、肾、脾血管在光学显微镜下的改变。结果:A 组视网膜、肾脏、脾脏血管形态和组织结构正常,B 组小动脉壁呈均质玻璃样变性,C 组血管结构基本正常。结论:红参对高血压性视网膜动脉硬化有预防作用。     

肝癌及癌旁组织中端粒酶检测的临床意义

目的研究端粒酶作为原发性肝细胞癌（ＨＣＣ）肿瘤标志物的可能性。方法采用ＴＲＡＰ方法检测了３３例原发性肝细胞癌及其３３例癌旁组织、４例肝转移癌及其４例癌旁组织、６例肝良性肿瘤和６例正常肝组织中的端粒酶活性。结果３３例原发性肝细胞癌组织中，有３０例端粒酶表达阳性，其阳性率为９０．９％。３３例癌旁组织中，有９例端粒酶表达阳性，其阳性率为２７．３％。４例肝转移癌端粒酶活性均阳性，４例癌旁组织中，２例端粒酶表达阳性。６例肝良性肿瘤中，仅１例端粒酶表达阳性。６例正常肝组织端粒酶表达均阴性。肝癌组织端粒酶表达与肿瘤临床病理特征无关。结论肝癌组织中普遍存在端粒酶活性表达，而良性和正常肝组织中端粒酶活性较少表达。端粒酶有可能成为诊断原发性肝细胞癌的肿瘤标志物     

大肠癌巨─微血管构筑的临床研究

为了探讨大肠癌和其间质血管的关系，我们研究了48例大肠癌标本不同部位的巨─-微血管构筑。方法：用癌瘤标本造影摄X线片、立体显微镜和微机图象定量分析。结果显示：癌中心血管稀疏或为无血管的坏死区及血管破坏；癌远近端瘤组织内血管增多增粗，畸形及紊乱；其血管定量参数与癌中心和癌远近端肠粘膜相比有显著差异（P＜O．05，P＜0．01）。结论：①大肠癌的发生发展依赖于血管形成和细胞增殖。②在理论上解释了大肠癌的临床病理过程。③大肠癌的恶性程度与其血管密度间似有负相关的趋势。④探讨了其临床应用价值。     

LOSS OF HETEROZYGOSITY ON CHROMOSOME 17p13.3 IN OVARIAN CANCER AND CERVICAL CANCER

ＣａｒｃｉｎｏｇｅｎｅｓｉｓｃｏｎｓｉｓｔｓｏｆｍｕｌｔｉｐｌｅｑｕａｌｉｔａｔｉｖｅｌｙｄｉｆｆｅｒｅｎｔｓｔｅｐｓｉｎｗｈｉｃｈａｃｃｕｍｍｕｌａｔｉｏｎｏｆＤＮＡａｌｔｅｒａｔｉｏｎｏｃｕｒｓａｎｄｃｒｉｔｉｃａｌｅｖｅｎｔｓ，ｉｎｖｏｌｖｉ...     

中药苦参汤中氧化苦参碱的含量测定

将苦参汤浸膏经索氏提取，硅胶预滤柱精制后，用ＴＬＣ－比色法测定其中氧化苦参碱的含量，测定波长λ＝４１８ｎｍ，回归方程Ｃ＝１５．８８４５ａ－０．０７５７８，ｒ＝０．９９９２，ｎ＝３。     

中药灯盏细辛化学成分的研究(Ⅰ)

研究灯盏细辛「Ｅｒｉｇｅｒｏｎ ｂｒｅｖｉｓｃａｐｕｓ（Ｖａｔ．）Ｈａｎｄ．－Ｍａｚｚ．」的化学成分。方法采用柱层析对灯盏细的苯溶解部位中的化学成分进行分离和纯化,应用理化党数和光谱分析（ＩＲ,ＭＳ,＾１Ｈ－ＮＭＲ,＾１３）鉴定其结构。结果：得到６个单体化合物,结构分别为木栓酮（ｆｒｉｅｄｅｌｉｎ,Ⅰ）木栓烷（ｆｒｉｅｄｅｌａｎｅ,Ⅱ）,木栓醇（ｆｒｉｅｄｅｌｉｎｏｌ,Ⅲ）,表木栓醇（ｅｐｉｆｒｉ     

救坤丹治疗子宫发育不良药理学研究

ＪＫＤ对醋酸致小鼠疼痛反应和缩宫素致小鼠痛经均有明显抑制作用，能使性未成熟小鼠子宫湿重和子宫系数增加。ＪＫＤ由阴道给药吸收，作用于子宫，可以通过镇药、增加子宫肌肉发育发挥治疗作用，即如中医认为有“补肾气，填精血，化寒积，破瘀血”之功效     

Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study

CONTEXT: Several reports from small clinical trials have suggested that estrogen replacement therapy may be useful for the treatment of Alzheimer disease (AD) in women. OBJECTIVE: To determine whether estrogen replacement therapy affects global, cognitive, or functional decline in women with mild to moderate AD. DESIGN: The Alzheimer's Disease Cooperative Study, a randomized, double-blind, placebo-controlled clinical trial conducted between October 1995 and January 1999. SETTING: Thirty-two study sites in the United States. PARTICIPANTS: A total of 120 women with mild to moderate AD and a Mini-Mental State Examination score between 12 and 28 who had had a hysterectomy. INTERVENTIONS: Participants were randomized to estrogen, 0.625 mg/d (n = 42), or 1.25 mg/d (n = 39), or to identically appearing placebo (n = 39). One subject withdrew after randomization but before receiving medication; 97 subjects completed the trial. MAIN OUTCOME MEASURES: The primary outcome measure was change on the Clinical Global Impression of Change (CGIC) 7-point scale, analyzed by intent to treat; secondary outcome measures included other global measures as well as measures of mood, specific cognitive domains (memory, attention, and language), motor function, and activities of daily living; compared by the combined estrogen groups vs the placebo group at 2, 6, 12, and 15 months of follow-up. RESULTS: The CGIC score for estrogen vs placebo was 5.1 vs 5.0 (P = .43); 80% of participants taking estrogen vs 74% of participants taking placebo worsened (P = .48). Secondary outcome measures also showed no significant differences, with the exception of the Clinical Dementia Rating Scale, which suggested worsening among patients taking estrogen (mean posttreatment change in score for estrogen, 0.5 vs 0.2 for placebo; P = .01). CONCLUSIONS: Estrogen replacement therapy for 1 year did not slow disease progression nor did it improve global, cognitive, or functional outcomes in women with mild to moderate AD. The study does not support the role of estrogen for the treatment of this disease. The potential role of estrogen in the prevention of AD, however, requires further research.     

肿瘤坏死因子、更生霉素和干扰素-γ联合应用对人卵巢癌裸鼠模型的协同作用

目的：研究联合应用肿瘤坏死因子（TNF）、干扰素－γ（IFN－γ）和更生霉素（KSM）对人卵巢癌裸鼠模型的协同作用。方法：将荷瘤裸鼠随机分成4组，分别用生理盐水、KSM、TNF＋IFN－γ、KSM＋TNF＋IFN－γ处理，观察肿瘤生长情况。结果：各组肿瘤相对体积比较，KSM组和KSM＋TNF＋IFN－γ组与对照组比较，差异有显著性（P＜0．05和P＜0．01）；TNF＋IFN－γ组与对照组比较，差异无显著性（P＞0．05），而KSM＋TNF＋IFN－γ组与KSM组比较，差异有显著性（P＜0．05）。结论：KSM与TNF、IFN－γ联合应用有协同抗卵巢癌细胞系3AO的作用，为临床应用提供了理论依据。